Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $84,429 | $193,598 | $196,449 | $230,131 |
| - Cash | $58,275 | $78,964 | $83,523 | $139,526 |
| + Debt | $60,226 | $60,661 | $61,671 | $62,075 |
| Enterprise Value | $86,380 | $175,295 | $174,597 | $152,680 |
| Revenue | $0 | $0 | $0 | $386 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$325 | -$331 | -$334 | $107 |
| % Margin | – | – | – | 27.7% |
| EBITDA | -$4,759 | -$21,614 | -$2,067 | -$62,776 |
| % Margin | – | – | – | -16,263.2% |
| Net Income | -$6,396 | -$23,327 | -$3,708 | -$64,384 |
| % Margin | – | – | – | -16,679.8% |
| EPS Diluted | -0.16 | -0.59 | -0.095 | -2.18 |
| % Growth | 72.9% | -520.4% | 95.6% | – |
| Operating Cash Flow | -$20,689 | -$29,667 | -$31,098 | -$18,565 |
| Capital Expenditures | $0 | $0 | $0 | -$38 |
| Free Cash Flow | -$20,689 | -$29,667 | -$31,098 | -$18,603 |